Dr. Rachel N. Grisham presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that the ...

Dr. Alexander B. Olawaiye presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that adding ...

Many women are afflicted by post-mastectomy pain syndrome, which spans from uncomfortable to disabling and can last years. It ...

Macrogenics (MGNX) stock rises as the FDA lifts a partial clinical hold on the company's Phase 2 LINNET trial for lead asset ...

Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, ...

Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, and existing screening ...

Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers ...

Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast ...

With a new U.S. green light in certain ovarian cancer patients, Corcept Therapeutics has redeemed its lead asset relacorilant after stumbling at the finish line in a separate indication late last year ...

Relacorilant plus nab-paclitaxel achieved a 35% reduction in mortality risk with a 4.1-month median overall survival improvement versus nab-paclitaxel alone in platinum-resistant disease. Dual primary ...

Merck (MRK) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's ...

The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...